Brief report on stroke prevention and treatment in China,2024

doi:10.3969/j.issn.1006-7795.2025.06.001

Abstract

Abstract: lthough China has a slight decline in stroke incidence in recent years, it still seems to be the leading health threat to Chinese citizens. China continues to bear a heavy stroke burden which has distinct epidemiological characteristics, while major risk factors remain prevalent and poorly controlled. Markedly, the government is putting effort into advancing the stroke prevention and treatment system, meanwhile, continuously funding cerebrovascular disease research, and driving steady improvements in diagnosis and treatment capabilities. However, stroke prevention and control work in China still faces considerable challenges. This report systematically reviews the current state of stroke prevention and treatment in China during 2023 from five perspectives: epidemiological characteristics, risk factors, diagnostic and therapeutic advances, prevention system development and stroke center construction, aiming to provide references for clinical practice.

Key words: stroke, incidence, prevalence, epidemiology, risk factor, China

CLC Number:

R743

Stroke Prevention Project, National Health Commission, Ji Xunming. Brief report on stroke prevention and treatment in China,2024[J]. Journal of Capital Medical University, 2025, 46(6): 947-960.

References

［1］Wang Y J, Li Z X, Gu H Q, et al. China stroke statistics: an update on the 2019 report from the national center for healthcare quality management in neurological diseases, China national clinical research center for neurological diseases, the Chinese stroke association, national center for chronic and non-communicable disease control and prevention, Chinese center for disease control and prevention and institute for global neuroscience and stroke collaborations［J］. Stroke Vasc Neurol, 2022, 7(5): 415－450.
［2］Institute for Health Metrics and Evaluation (IHME). GBD Results［R］. Seattle: University of Washington, 2025.
［3］Ma Q F, Li R, Wang L J, et al. Temporal trend and attributable risk factors of stroke burden in China, 1990－2019: an analysis for the Global Burden of Disease Study 2019［J］. Lancet Public Health, 2021, 6(12): e897－e906.
［4］Xu J, Zhang X, Jin A M, et al. Trends and risk factors associated with stroke recurrence in China, 2007－2018［J］. JAMA Netw Open, 2022, 5(6): e2216341.
［5］国家卫生健康委员会. 2023中国卫生健康统计年鉴［M］. 北京: 中国协和医科大学出版社, 2024.
［6］Tu W J, Chao B H, Ma L, et al. Case-fatality, disability and recurrence rates after first-ever stroke: a study from bigdata observatory platform for stroke of China［J］. Brain Res Bull, 2021, 175: 130－135.
［7］Tu W J, Zhao Z P, Yin P, et al. Estimated burden of stroke in China in 2020［J］. JAMA Netw Open, 2023, 6(3): e231455.
［8］Jin C Y, Lai Y X, Li Y Z, et al. Changes in the prevalence of diabetes and control of risk factors for diabetes among Chinese adults from 2007 to 2017: an analysis of repeated national cross-sectional surveys［J］. J Diabetes, 2024, 16(2): e13492.
［9］Shi Q Y, Nong K L, Vandvik P O, et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials［J］. BMJ, 2023, 381: e074068.
［10］Xia Q H, Chen Y Q, Yu Z J, et al. Prevalence, awareness, treatment, and control of dyslipidemia in Chinese adults: a systematic review and meta-analysis［J］. Front Cardiovasc Med, 2023, 10: 1186330.
［11］Yang X H, Zhang B L, Cheng Y, et al. Association of remnant cholesterol with risk of cardiovascular disease events, stroke, and mortality: a systemic review and meta-analysis［J］. Atherosclerosis, 2023, 371: 21－31.
［12］Liu Y T, Jin X L, Fu K L, et al. Non-traditional lipid profiles and the risk of stroke: a systematic review and meta-analysis［J］. Nutr Metab Cardiovasc Dis, 2023, 33(4): 698－714.
［13］Zhang T T, Liang Z R, Lin T F, et al. Cost-effectiveness of folic acid therapy for primary prevention of stroke in patients with hypertension［J］. BMC Med, 2022, 20(1): 407.
［14］Lu X T, Wang Y N, Mo Q W, et al. Effects of low-dose B vitamins plus betaine supplementation on lowering homocysteine concentrations among Chinese adults with hyperhomocysteinemia: a randomized, double-blind, controlled preliminary clinical trial［J］. Eur J Nutr, 2023, 62(4): 1599－1610.
［15］Shi S B, Tang Y H, Zhao Q Y, et al. Prevalence and risk of atrial fibrillation in China: a national cross-sectional epidemiological study［J］. Lancet Reg Health West Pac, 2022, 23: 100439.
［16］Wei Y, Zhou G Q, Wu X Y, et al. Latest incidence and electrocardiographic predictors of atrial fibrillation: a prospective study from China［J］. Chin Med J, 2023, 136(3): 313－321.
［17］Shang L X, Zhang Y J, Zhao Y, et al. Contemporary oral anticoagulant therapy of patients with atrial fibrillation in China: status, obstacles, and strategies for improvement［J］. Biosci Trends, 2022, 16(5): 317－329.
［18］Fan J H, Li X G, Yu X Y, et al. Global burden, risk factor analysis, and prediction study of ischemic stroke, 1990－2030［J］. Neurology, 2023, 101(2): e137－e150.
［19］Liang T, Xie C P, Lv B J, et al. Age at smoking initiation and smoking cessation influence the incidence of stroke in China: a 10-year follow-up study［J］. J Thromb Thrombolysis, 2023, 56(1): 175－187.
［20］中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国缺血性卒中和短暂性脑缺血发作二级预防指南2022［J］. 中华神经科杂志, 2022, 55(10): 1071－1110.
［21］Zuo X, Zhao R, Wu M, et al. Soy consumption and the risk of type 2 diabetes and cardiovascular diseases: a systematic review and Meta-analysis［J］. Nutrients, 2023, 15(6)：1358.
［22］Wang L M, Zhou B, Zhao Z P, et al. Body-mass index and obesity in urban and rural China: findings from consecutive nationally representative surveys during 2004－18［J］. Lancet, 2021, 398(10294): 53－63.
［23］Yawoot N, Govitrapong P, Tocharus C, et al. Ischemic stroke, obesity, and the anti-inflammatory role of melatonin［J］. Biofactors, 2021, 47(1): 41－58.
［24］Ye J Y, Hu Y J, Chen X R, et al. Association between the weight-adjusted waist index and stroke: a cross-sectional study［J］. BMC Public Health, 2023, 23(1): 1689.
［25］Qi W W, Ma J, Guan T J, et al. Risk factors for incident stroke and its subtypes in China: a prospective study［J］. J Am Heart Assoc, 2020, 9(21): e016352.
［26］Luo L, Meng H N, Wang Z W, et al. Effect of high-intensity exercise on cardiorespiratory fitness in stroke survivors: a systematic review and meta-analysis［J］. Ann Phys Rehabil Med, 2020, 63(1): 59－68.
［27］Wu H, Zhang B Y, Wei J, et al. Short-term effects of exposure to ambient PM1, PM2.5, and PM10 on ischemic and hemorrhagic stroke incidence in Shandong province, China［J］. Environ Res, 2022, 212(Part C): 113350.
［28］Shu M J, Li J R, Zhu Y C, et al. Migraine and ischemic stroke: a mendelian randomization study［J］. Neurol Ther, 2022, 11(1): 237－246.
［29］Yuan J, Lu Z K, Xiong X M, et al. Age and geographic disparities in acute ischaemic stroke prehospital delays in China: a cross-sectional study using national stroke registry data［J］. Lancet Reg Health West Pac, 2023, 33: 100693.
［30］Chen Y J, Ying M, Chen L H. Application effect of prehospital-hospital integrated emergency nursing in patients with acute cerebral infarction［J］. Biotechnol Genet Eng Rev, 2024, 40(4): 4407－4419.
［31］Song H Q, Wang Y, Ma Q F, et al. Efficacy and safety of recombinant human prourokinase in the treatment of acute ischemic stroke within 4.5 hours of stroke onset: a phase 3 randomized clinical trial［J］. JAMA Netw Open, 2023, 6(7): e2325415.
［32］Wang Y J, Li S Y, Pan Y S, et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial［J］. Lancet, 2023, 401(10377): 645－654.
［33］Chen H S, Cui Y, Zhou Z H, et al. Dual antiplatelet therapy vs alteplase for patients with minor nondisabling acute ischemic stroke: the ARAMIS randomized clinical trial［J］. JAMA, 2023, 329(24): 2135－2144.
［34］Bai X S, Zhang X, Gong H Z, et al. Different types of percutaneous endovascular interventions for acute ischemic stroke［J］. Cochrane Database Syst Rev, 2023, 5(5): CD014676.
［35］Zhao C H, Hu T, Kong W L, et al. First-pass effect in patients with acute basilar artery occlusions undergoing stent retriever thrombectomy［J］. J Neurosurg, 2023, 138(3): 693－700.
［36］Huo X C, Ma G T, Tong X, et al. Trial of endovascular therapy for acute ischemic stroke with large infarct［J］. N Engl J Med, 2023, 388(14): 1272－1283.
［37］Li Q, Abdalkader M, Siegler J E, et al. Mechanical thrombectomy for large ischemic stroke: a systematic review and meta-analysis［J］. Neurology, 2023, 101(9): e922－e932.
［38］Deng Q W, Zhang L, Liu Y K, et al. Effect of time window on endovascular thrombectomy with or without intravenous thrombolysis in acute ischemic stroke: results from DIRECT-MT［J］. Cerebrovasc Dis, 2024, 53(2): 176－183.
［39］Kang Z M, Wu L S, Sun D, et al. Proximal hyperdense middle cerebral artery sign is associated with increased risk of asymptomatic hemorrhagic transformation after endovascular thrombectomy: a multicenter retrospective study［J］. J Neurol, 2023, 270(3): 1587－1599.
［40］Sarraj A, Hassan A E, Abraham M G, et al. Trial of endovascular thrombectomy for large ischemic strokes［J］. N Engl J Med, 2023, 388(14): 1259－1271.
［41］Wang Y, Ma H R, Zhang Q H, et al. Factors affecting the outcomes of tirofiban after endovascular treatment in acute ischemic stroke: experience from a single center［J］. CNS Neurosci Ther, 2023, 29(3): 957－967.
［42］Liu H H, Jing J, Wang A X, et al. Stroke recurrence and antiplatelets in posterior versus anterior circulation minor stroke or transient ischemic attack［J］. Stroke, 2023, 54(4): 964－972.
［43］Zhang J, Wang A X, Tian X, et al. Impact of body mass index on efficacy and safety of ticagrelor versus clopidogrel in patients with minor stroke or transient ischemic attack［J］. CMAJ, 2023, 195(26): E897－E904.
［44］Jing J, Xie X W, Johnston S C, et al. Genotype-guided dual antiplatelet use for transient ischemic attack and minor stroke by imaging status: subgroup analysis of the CHANCE-2 trial［J］. Ann Neurol, 2023, 93(4): 783－792.
［45］Zhang X G, Jiang S S, Xue J, et al. Personalized antiplatelet therapy guided by clopidogrel pharmacogenomics in acute ischemic stroke and transient ischemic attack: a prospective, randomized controlled trial［J］. Front Pharmacol, 2022, 13: 931405.
［46］Zhai Y J, Shi M Y, Liu Y, et al. Magnitude of systolic blood pressure reduction and early achieved blood pressure and clinical outcomes after acute ischemic stroke［J］. J Am Heart Assoc, 2023, 12(20): e030692.
［47］Du L Z, Zhang Y Q, Li X H, et al. Blood pressure excursion on admission and intravenous thrombolysis in ischemic stroke［J］. J Hypertens, 2023, 41(8): 1265－1270.
［48］Cai W M, Li Y L, Guo K, et al. Association of glycemic variability with death and severe consciousness disturbance among critically ill patients with cerebrovascular disease: analysis of the MIMIC-IV database［J］. Cardiovasc Diabetol, 2023, 22(1): 315.［49］Turan N, Heider R A J, Zaharieva D, et al. Sex differences in the formation of intracranial aneurysms and incidence and outcome of subarachnoid hemorrhage: review of experimental and human studies［J］. Transl Stroke Res, 2016, 7(1): 12－19.
［50］Vlak M H, Algra A, Brandenburg R, et al. Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis［J］. Lancet Neurol, 2011, 10(7): 626－636.
［51］Chen Y P, Wright N, Guo Y, et al. Mortality and recurrent vascular events after first incident stroke: a 9-year community-based study of 0·5 million Chinese adults［J］. Lancet Glob Health, 2020, 8(4): e580－e590.
［52］Connolly E S Jr, Rabinstein A A, Carhuapoma J R, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American heart association/American stroke association［J］. Stroke, 2012, 43(6): 1711－1737.
［53］Virani S S, Alonso A, Aparicio H J, et al. Heart disease and stroke statistics－2021 update: a report from the American heart association［J］. Circulation, 2021, 143(8): e254－e743.
［54］Su J B, Cao J, Yang H, et al. Diagnosis of unruptured intracranial aneurysm by high-performance serum metabolic fingerprints［J］. Small Methods, 2023, 7(3): 2201486.
［55］Liu J M, Zhou Y, Li Y, et al. Parent artery reconstruction for large or giant cerebral aneurysms using the tubridge flow diverter: a multicenter, randomized, controlled clinical trial (PARAT)［J］. AJNR Am J Neuroradiol, 2018, 39(5): 807－816.
［56］Zhang H Y, Li L, Zhang H Q, et al. Small and medium-sized aneurysm outcomes following intracranial aneurysm treatment using the pipeline embolization device: a subgroup analysis of the PLUS registry［J］. Front Neurol, 2022, 13: 881353.
［57］Chen J M, Wang L M, Xu H, et al. Meningeal lymphatics clear erythrocytes that arise from subarachnoid hemorrhage［J］. Nat Commun, 2020, 11(1): 3159.

[1]	Zhang Xiaowen, Tang Tao, Li Di, Li Shen, Xi Chunjiang. Analysis of the risk factors of the infarct growth rate in acute anterior circulation large vessel occlusion [J]. Journal of Capital Medical University, 2025, 46(4): 688-693.
[2]	Guo Yu, Chen Weiguan, Zhou Sanlian, Tang Liqiao, Sun Wangyan, Zhang Dongmei, Lu Hongjian. Correlation between serum glycoprotein non-metastatic melanoma protein B levels and disease severity and prognosis in patients with acute ischemic stroke [J]. Journal of Capital Medical University, 2025, 46(4): 702-709.
[3]	Jing Jiao, Zhang Siyao, Liu Yanling, Wang Fen, Xiao Wei, Wang Zhenzhong. Effect of large artery atherosclerosis subtype on the efficacy of Ginkgo Diterpene Lactone Meglumine in acute ischemic stroke [J]. Journal of Capital Medical University, 2025, 46(2): 228-233.
[4]	Zi Xiaohui, Xia Xue, Li jing, Zhang Xiaoli, Zhou Quan, Wang Anxin, Wang Yilong. Advances in the application of antiplatelet therapy in intravenous thrombolysis for acute ischemic stroke patients [J]. Journal of Capital Medical University, 2025, 46(2): 234-242.
[5]	Dong Xiao, Zhang Wanying, Ji Xunming, Wu Chuanjie. Overview of the “2024 Guideline for the Primary Prevention of Stroke: A Guideline from the American Heart Association(AHA)/American Stroke Association(ASA)” [J]. Journal of Capital Medical University, 2025, 46(1): 1-5.
[6]	Stroke Prevention Project, National Health Commission, Ji Xunming. Promoting the Stroke Prevention Project, National Health Commission: current status and strategy of stroke prevention and treatment in China [J]. Journal of Capital Medical University, 2025, 46(1): 11-14.
[7]	Chu Xuehong, Shen Yingjie, Wang Yaolou, Dong Xiao, Liu Yuanyuan, Feng Yan, Jiang Miaowen, Li Ming, Ji Xunming, Wu Chuanjie. Exploring the causal relationship between extensive perivascular space burden and ischemic stroke and its subtypes and transient ischemic attack based on Mendelian randomization [J]. Journal of Capital Medical University, 2025, 46(1): 22-33.
[8]	Wang Yinping, Meng Cancan, Wu Wenjuan, Yang Zhitang. The expressions of CD62P, CD40L, and Rev-erbα after ischemic stroke on different onset times [J]. Journal of Capital Medical University, 2025, 46(1): 34-40.
[9]	Zhan Yanli, Li Yiyin, Li Ping, Sun Jingping, Huang Liangtong, Cai Xueli. Analysis of the current status and efficacy of acute ischemic stroke treatment based on hierarchical medical service network [J]. Journal of Capital Medical University, 2025, 46(1): 41-47.
[10]	Yang Xiao, Meng Yuanyuan, Yang Jingyi, Wang Shuhan, Zhang Ligong. Predictive value of atherogenic index of plasma index, triglyceride-glucose index and cerebral small vascular disease imaging markers on early neurological response after intravenous thrombolysis in patients with acute ischemic stroke [J]. Journal of Capital Medical University, 2025, 46(1): 48-55.
[11]	Zhang Meng, Ma Yongxin, Jia Qiong , Zhang Dongwei, Zhang Xinhong, Xu Yaoming . Clinical observation on the efficacy and safety of intravenous thrombolysis in the treatment of acute mild non-disabling ischemic stroke: a single-center retrospective observational study [J]. Journal of Capital Medical University, 2025, 46(1): 56-62.
[12]	Liu Xiaomeng, Zhou Shaojuan, Shao Xiaohong, Xu Wenping, Huan Feng, Zhu Xiangyang. Current situation and four-level prevention of stroke under the collaborative management model between medical prevention and treatment in Nantong [J]. Journal of Capital Medical University, 2025, 46(1): 63-67.
[13]	Qiao Yue, Li Chuanhui, Zhao Wenbo. The current status and future directions of reperfusion therapy for acute ischemic stroke [J]. Journal of Capital Medical University, 2025, 46(1): 68-70.
[14]	Li Xingmao, Li Xiu, Wang Ting, Zhao Xin, Wang Deyang, Shang Haiyan, Zhao Yongmei, Li Sen. Effects of GLP-1 receptor agonists on cognitive function in patients with type 2 diabetes mellitus after acute ischemic stroke [J]. Journal of Capital Medical University, 2024, 45(6): 1029-1037.
[15]	Shen Tong, Li Fangfang, Fan Junfen, Luo Yumin. Correlation analysis of plasma YAP level with stroke prognostic factors and post-stroke inflammation [J]. Journal of Capital Medical University, 2024, 45(6): 1071-1078.